Evaluation of Effectiveness of GSK Biologicals' Pneumococcal Conjugate Vaccine 1024850A Against Invasive Disease

Inclusion Criteria: * Male or female between, and including, 6 weeks to 18 months of age at the time of the first vaccination. * Written informed consent obtained from parent(s) or from the guardian(s) of the subject. Exclusion Criteria: * Previous vaccination with any registered, non-registered or investigational pneumococcal vaccine other than the study vaccine, or planned use during the study period. If a child belongs to a high risk group for pneumococcal infections for which a licensed pneumococcal conjugate vaccine is made locally available, the subject can not be enrolled in the study and should be referred to the specific immunization program. * Previous vaccination against Hepatitis B virus with any registered, non-registered or investigational vaccine, or planned use of such a vaccine other than the study vaccine during the study period. * Previous vaccination against Hepatitis A virus with any registered, non-registered or investigational vaccine, or planned use of such a vaccine other than the study vaccine during the study period. * Known severe hypersensitivity to any component of the study vaccines, including neomycin. * Any medical condition that would contraindicate the initiation of routine immunization outside a clinical trial context.